The first Australian data into the efficacy of repeated low-level red-light (RLRL) has been published in what is shaping to...
Read moreDetailsThe Essilor Stellest lens, clinically proven to slow myopia progression in children,^1 has now been evaluated in two studies for...
Read moreDetailsThe inventor of the Eyerising International repeated low-level red light (RLRL) therapy for myopia, Professor Mingguang He, has outlined “notable...
Read moreDetailsThe latest one-year and two-year results from ongoing multi-centre trials of ZEISS MyoCare lenses consistently demonstrate the slowing of progressive...
Read moreDetailsAt the completion of this article, the reader should be able to improve their knowledge of emerging myopia control interventions,...
Read moreDetailsEssilorLuxottica has unveiled new six-year clinical data at the 2025 China Optometry & Ophthalmology Conference (COOC), reinforcing the long-term efficacy...
Read moreDetailsSydney optometrist DR OLIVER WOO explains why colleagues need to be on the look out for pre-myopes and how prescribing...
Read moreDetailsThere’s a lot to think about when faced with a progressing myope. Is their script up to date? Is the...
Read moreDetailsCooperVision’s MiSight 1 day is a key product helping slow the progression of myopia in children. As optometry increasingly embraces...
Read moreDetailsKorea-based global pharmaceutical company Celltrion has announced approval from the Therapeutic Goods Administration (TGA) of Australia of its ophthalmic treatment...
Read moreDetailsInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited